Alexander B. Sigalov, Ph.D.
President and Founder
Alexander B. Sigalov, Ph.D. has extensive academic and industry experience. As a scientist with more than 70 scientific publications in different fields of his expertise, Dr. Sigalov is world-renowned for his leadership in biophysics, immunology, and atherosclerosis. He is founding Editor-in-Chief of Self/Nonself, a new multidisciplinary journal that focuses on both the fundamental science and clinical aspects of immunology.
In the ‘90s, Dr. Sigalov founded the AMW Biomed Company (Moscow, Russia) where he developed and marketed in Russia the first diagnostic kits for heart disease and stroke serving more than 80 institutional customers. AMW Biomed also commercialized human apolipoproteins and was official supplier of these proteins to the DAKO Company in Denmark.
Prior to founding SignaBlok, Dr. Sigalov worked at Massachusetts Institute of Technology, where he discovered an unusual biophysical phenomenon, the homooligomerization of intrinsically disordered proteins. Later, as a faculty at the University of Massachusetts Medical School, he used this discovery to develop a novel model of receptor signaling, the Signaling Chain HOmoOLigomerization (SCHOOL) model, and the related concept of modulation of cell response.
Dr. Sigalov is the sole inventor of methods and compositions created through the SCHOOL platform that can be used to prevent or treat multiple serious diseases with unmet needs. He also developed integrated nanosystems for targeted delivery of therapeutics and imaging agents to macrophage-rich sites of disease in vivo.
Dr. Sigalov holds a Ph.D. in Organic Chemistry and M.S. in Chemistry from Moscow State University (Moscow, Russia).